Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 51

INNOVATIVE MODELS OF THE BRAIN MICROENVIRONMENT TO IDENTIFY NEW TREATMENTS ...

Brain tumours are the leading cause of disease related mortality in children, with medulloblastoma (MB) representing the most common malignant paediatric brain tumour. The outcome for high-risk patients however remains poor and survivors frequently relapse. We have developed a novel computational approach to identify networks of signalling proteins that drive ...

Modulation of intra-tumor hypoxia to sensitize DIPG irradiation and initiate ...

Malignant gliomas in specific region like brain pons are not curable as they cannot be surgically resected and are only transiently benefiting from local irradiation and in some cases from targeted therapies. These aggressive brain tumors are molecularly well known as they are characterized by a driver mutation. This abnormality ...

Targeting hypoxia and mitochondrial metabolism with repurposing drugs as an ...

Abstract Diffuse intrinsic pontine glioma (DIPG) is a rare and incurable brain tumor that arises in the brainstem of children predominantly between the ages of 6 and 9.  Unlike many brain tumors, DIPGs cannot be removed through surgery due to its sensitive location. The standard of care today remains radiation therapy (...

Targeting DIPG through pharmacological activation of mitochondrial biogenesis: as in ...

Diffuse intrinsic pontine gliomas (DIPG) are infiltrative, highly aggressive pediatric brainstem tumors with limited therapeutic options. Despite international efforts to improve outcome, DIPG show poor response to conventional radiation and chemotherapeutic strategies. Only within the last decade have studies really begun to decipher the molecular mechanisms behind DIPG tumorigenesis, with ...

Targeting EZH2 as a theraputic strategy in DIPG

Malignant brain tumors are the leading cause of cancer-related mortality in children (1), and diffuse intrinsic pontine glioma (DIPG) is one of the most devastating, with a median survival of <1 year following treatment with radiation therapy (2). Despite more than 250 clinical trials over the past 30 years (3), not a single chemotherapeutic agent ...